comparison the therapeutic effect of pioglitazone and carnitine to pioglitazone and vitamin E in patients with non alcoholic fatty liver disease

Phase 3

• Conditions: on alcoholic fatty liver disease.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20190701044062N8
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients with non alcoholic fatty liver disease

Exclusion Criteria

Patients with liver disease such as viral hepatitis, autoimmune hepatitis, Wilson, hemochromatosis, liver cirrhosis, and PBC and PSC
Patients who drink alcohol
Patients with renal Failure (Creatinine > 1.5 mg/dl)
Patients with known severe systemic disease and malignancy.
Pregnancy or breastfeeding
Patients with type 1 diabetes

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
iver enzymes levels. Timepoint: At baseline, 3 and 6 months after the intervention. Method of measurement: Laboratory methods.;Ultrasound grade. Timepoint: At baseline and 6 months after intervention. Method of measurement: Perform liver ultrasound.

Secondary Outcome Measures

Name	Time	Method
. Timepoint: . Method of measurement: .